Clinical Trial Finder

Inclusion Criteria:

• - Participants with histologically confirmed B-cell malignancy, failed or intolerant to either ≥ 2 prior standard/common regimens given in combination or sequentially OR have received 1 prior BTK-containing regimen, relapse/refractory, and with treatment indication: - CLL/SLL treated with prior immunochemistry or BTK inhibitor containing regimen; - DLBCL treated with prior CD20 or anthracyclines containing regimen; - Other types of B-cell NHL treated with prior CD20 containing regimen.

• - Adequate organ function, defined by the following laboratory parameters: - Hematologic: - Absolute neutrophil count (ANC) ≥ 0.75×10^9/L, and ≥ 0.5×10^9/L if bone marrow involved.

• - Platelets ≥ 50×10^9/L without transfusion within 7 days, and ≥ 30×10^9/L if bone marrow involved.

• - Hemoglobin ≥ 8.0 g/dL without transfusion within 7 days, and ≥ 7.0 g/dL if bone marrow involved.

• - Coagulation: - Prothrombin time (PT) ≤ 1.5 × ULN.

• - Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.

• - Renal function: - Creatinine clearance ≥ 30 mL/min estimated glomerular filtration rate based on Cockcroft-Gault formula.

• - Liver function: - Total bilirubin ≤ 1.5 × ULN (unless due to Gilbert's disease) - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related.

Exclusion Criteria:

• - Women who are pregnant or lactating.

• - Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to < 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator) - Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening ECG abnormalities.

• - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

• - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the following: - Active graft versus host disease (GvHD); - Cytopenias from incomplete blood cell count recovery post-transplant; - Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy; - Ongoing immunosuppressive therapy.

- Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation

The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort.

Arms

Experimental: Dose Escalation for TT-01488

TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.

Experimental: Dose Expansion for TT-01488

TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.

Interventions

Drug: - TT-01488 Tablets

TT-01488 tablet will be administered orally once daily per protocol defined schedule.